临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)
classification,279–282 282
cytogenetics for diagnosis and prediction,299–310,314–315,323 323
endpoints in clinical trials event-free survival,311–313 313
relapse-free interval,313 313
non-inferiority trials,190 190
per protocol analysis comparison,146–149 149
run-in period,58,61,150 150
start date for endpoints,162–163 163
Interactive voice response system (IVRS)applications,125–126 126
Interferon-α adverse events,418–419 419
gene expression response,530–531 531
hepatitis C management,371,411–412,525–526 526
response,525–526,528–531 531
multiple sclerosis trial,407–408 408
Interferon-β multiple sclerosis management,408,508–509 509
Interferon-γ hepatitis C virus response,525–527 527
Chronic obstructive pulmonary disease (COPD)health-related quality of life,405 405
Cilloni study,320–322 322
Cisplatin black box warning,565–566 566
Cladribine multiple sclerosis management,509–510 510
Clinical endpoint,191 191
Clinical research associate (CRA)functions,111,441 441
Clinical Review,601–602 602